• 5 min read
• Published on 6 January 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
Let's be frank. For decades, the most effective weight loss treatments involved a needle. And if there’s one thing that puts people off, it’s having to jab themselves every week. It’s inconvenient, it’s a bit clinical, and for many, it’s a psychological hurdle too high to clear. But what if you could package that same revolutionary science into a simple, easy-to-swallow pill? Well, that’s not a hypothetical question anymore, and I think it’s about to change the game entirely.
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
The shift from an injection to a daily tablet is, to me, the single biggest catalyst this market has seen. It’s the difference between a niche medical treatment and a mainstream phenomenon. Think about it. We’ve seen this before. When birth control went from invasive procedures to a simple pill, the market exploded. The same happened with countless other treatments. Convenience isn’t just a nice-to-have, it is the primary driver of mass adoption. Suddenly, a treatment that was accessible to a few thousand brave souls might become palatable to millions. The potential addressable market hasn't just grown, it has multiplied by an order of magnitude. This is where a shrewd investor’s ears should prick up.
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
Naturally, where there’s a potential gold rush, you’ll find the usual suspects. Novo Nordisk, the Danish giant, has fired the starting gun with its oral formulation. They have spent years laying the groundwork in diabetes and obesity research, and this could well be their crowning achievement. But don't for a moment think their rivals are sitting on their hands. Across the pond, Eli Lilly is throwing everything it has at developing its own oral alternatives. This is a classic heavyweight bout between two established titans, and for investors, it means backing a horse with a proven track record. For a deeper dive into this specific market, you might want to read this piece on Oral Obesity Treatments: Investment Theme Explained.
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
What I find fascinating is that the story doesn't end with the pill manufacturers. A whole new ecosystem is springing up around distribution. Companies like Hims & Hers aren’t bothering with the messy business of drug discovery. Instead, they are positioning themselves as the digital gatekeepers. They offer a slick, telehealth platform that connects patients with prescribers, cutting out the hassle of a traditional doctor's visit. As treatment becomes as simple as taking a daily tablet, these digital platforms could become incredibly powerful. They’re the ones building the relationship with the end consumer, and in the modern economy, that relationship is often where the real value lies.
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
Now, before you rush off to remortgage the house, a dose of reality is required. This is pharmaceuticals, not a sure bet at the Grand National. Clinical-stage companies offer the allure of ground-floor investing, but the vast majority will fail to get their products over the regulatory finish line. That’s a high-risk, high-reward punt if ever I saw one. Even the big players face immense pressure on pricing, and the threat of a competitor launching a slightly better pill is ever-present. Investing here requires a strong stomach and an acceptance that fortunes can be made, but they can just as easily be lost. The market dynamics could change in a heartbeat.
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
View the full Basket:Oral Obesity Treatments: Investment Theme Explained
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article